Company Announcements

Further re Scrip Dividend

Source: RNS
RNS Number : 4936Z
IP Group PLC
14 September 2022


14 September 2022


IP Group plc - Further re Scrip Dividend



IP Group plc (LSE: IPO) ("IP Group" or "the Group" or "the Company"), which develops world-changing science and technology businesses across life sciences, technology and cleantech, announces that, further to the announcements dated 03 August 2022, 18 August 2022 and 13 September 2022 in connection with the Interim Scrip Dividend, the Group has received valid elections from shareholders resulting in a requirement to issue 154,718 new ordinary shares of 2p each ("New Shares"). 


An application has been made for the New Shares to be issued in connection with the Scrip Dividend to be admitted to the premium segment of the Official List of the Financial Conduct Authority and to trading on the main market for listed securities of the London Stock Exchange respectively.


Admission of the New Shares is expected to be effective on 20 September 2022. Following admission and in accordance with the Disclosure Guidance and Transparency Rules of the Financial Conduct Authority, the Group will have 1,063,188,005 Ordinary Shares in issue and 28,607,622 Ordinary Shares in Treasury.


The total number of Ordinary Shares with voting rights following the issue of the New Shares will be 1,034,580,383 Ordinary Shares. This figure may be used by shareholders in the Group as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Group under the Disclosure Guidance and Transparency Rules of the Financial Conduct Authority.


For more information, please contact:


IP Group plc

David Baynes, Chief Financial and Operating Officer
Liz Vaughan-Adams, Communications           

+44 (0) 20 7444 0050
+44 (0) 20 7444 0062/+44 (0) 7967 312125


Notes for editors


About IP Group


IP Group develops world-changing science and technology businesses across life sciences, technology and cleantech (through Kiko Ventures). The Group has a strong track record of success, having been the founder investor in a number of high-profile companies including Oxford Nanopore Technologies plc, and has one of the most exciting portfolios of high-growth businesses in Europe. The Group also owns Parkwalk, the UK's largest growth EIS fund manager which backs world-changing technologies emerging from the UK's leading universities and research institutions. IP Group is listed on the Main Market of the London Stock Exchange under the code IPO.


For more information, please visit our website at





This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.